Novo Nordisk shifts GLP-1 drug messaging from medical treatment to lifestyle improvement
Novo Nordisk is changing how it markets its GLP-1 drugs by emphasizing lifestyle benefits rather than treating obesity as a medical condition.
Marketing slogans highlight general wellness
Advertisements around the world now feature slogans such as Live lighter and Summer Glow Up. The company promotes these products as ways to look and feel better generally instead of focusing solely on weight management.
Website language changes drug classification
On its website, Novo Nordisk no longer labels Wegovy as a weight management or anti-obesity medicine. Instead the company describes the treatment simply as a weight loss drug for customers.
Terminology shifts from patients to customers
The firm increasingly refers to people taking its drugs as customers rather than patients. This approach marks a departure from earlier promotions that addressed obesity strictly as a medical issue.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.